Equities research analysts predict that Bruker Co. (NASDAQ:BRKR) will post $454.83 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Bruker’s earnings, with estimates ranging from $448.64 million to $462.36 million. Bruker reported sales of $431.70 million during the same quarter last year, which indicates a positive year-over-year growth rate of 5.4%. The business is scheduled to report its next earnings results on Thursday, May 2nd.
According to Zacks, analysts expect that Bruker will report full year sales of $2.02 billion for the current financial year. For the next fiscal year, analysts anticipate that the company will post sales of $2.11 billion, with estimates ranging from $2.10 billion to $2.13 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Bruker.
Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Monday, February 11th. The medical research company reported $0.54 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.54. The firm had revenue of $553.60 million during the quarter, compared to analysts’ expectations of $544.53 million. Bruker had a net margin of 9.48% and a return on equity of 26.36%.
BRKR has been the subject of several recent analyst reports. Zacks Investment Research cut shares of Bruker from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 7th. BTIG Research restated a “buy” rating and issued a $44.00 target price (up previously from $42.00) on shares of Bruker in a research note on Tuesday, February 12th. Needham & Company LLC initiated coverage on shares of Bruker in a research note on Wednesday, January 2nd. They issued a “strong-buy” rating and a $39.00 target price for the company. BidaskClub upgraded shares of Bruker from a “hold” rating to a “buy” rating in a research note on Friday, January 11th. Finally, Deutsche Bank upgraded shares of Bruker from a “hold” rating to a “buy” rating and raised their target price for the stock from $40.00 to $50.00 in a research note on Friday, April 12th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Hold” and an average target price of $38.14.
Several institutional investors and hedge funds have recently made changes to their positions in BRKR. Hanseatic Management Services Inc. increased its holdings in Bruker by 52.0% during the 4th quarter. Hanseatic Management Services Inc. now owns 1,692 shares of the medical research company’s stock valued at $50,000 after acquiring an additional 579 shares in the last quarter. Captrust Financial Advisors increased its holdings in Bruker by 164.7% during the 4th quarter. Captrust Financial Advisors now owns 1,824 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 1,135 shares in the last quarter. SG Americas Securities LLC purchased a new position in Bruker during the 4th quarter valued at about $176,000. GAM Holding AG purchased a new position in Bruker during the 3rd quarter valued at about $211,000. Finally, Comerica Bank purchased a new position in Bruker during the 4th quarter valued at about $219,000. Institutional investors and hedge funds own 68.89% of the company’s stock.
NASDAQ:BRKR traded down $0.41 during trading hours on Friday, reaching $38.51. 4,850 shares of the company’s stock were exchanged, compared to its average volume of 700,331. The stock has a market cap of $6.09 billion, a P/E ratio of 27.49, a P/E/G ratio of 2.18 and a beta of 1.47. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.18 and a quick ratio of 1.33. Bruker has a 1-year low of $26.10 and a 1-year high of $40.25.
The business also recently declared a quarterly dividend, which was paid on Friday, March 22nd. Stockholders of record on Tuesday, March 5th were issued a $0.04 dividend. The ex-dividend date was Monday, March 4th. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.42%. Bruker’s dividend payout ratio is presently 11.43%.
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Recommended Story: How do investors use RSI to grade stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.